Mackenzie Financial’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-153,330
| Closed | -$6.17M | – | 1562 |
|
|
2026
Q1 | $6.17M | Buy |
153,330
+57,119
| +59% | +$1.23M | 0.01% | 616 |
|
|
2025
Q4 | $2.42M | Buy |
96,211
+19,500
| +25% | +$458K | ﹤0.01% | 802 |
|
|
2025
Q3 | $1.74M | Buy |
76,711
+2,546
| +3% | +$59.4K | ﹤0.01% | 887 |
|
|
2025
Q2 | $1.28M | Buy |
74,165
+32,632
| +79% | +$604K | ﹤0.01% | 952 |
|
|
2025
Q1 | $908K | Buy |
41,533
+5,175
| +14% | +$143K | ﹤0.01% | 1008 |
|
|
2024
Q4 | $1.16M | Sell |
36,358
-9,127
| -20% | -$274K | ﹤0.01% | 908 |
|
|
2024
Q3 | $1.31M | Buy |
45,485
+37,546
| +473% | +$1.39M | ﹤0.01% | 810 |
|
|
2024
Q2 | $305K | Sell |
7,939
-23,082
| -74% | -$1.05M | ﹤0.01% | 1162 |
|
|
2024
Q1 | $1.82M | Sell |
31,021
-10,464
| -25% | -$667K | ﹤0.01% | 756 |
|
|
2023
Q4 | $2.48M | Buy |
+41,485
| New | +$2.1M | ﹤0.01% | 688 |
|
|
2023
Q3 | – | Sell |
-10,007
| Closed | -$893K | – | 1472 |
|
|
2023
Q2 | $893K | Sell |
10,007
-7,655
| -43% | -$660K | ﹤0.01% | 884 |
|
|
2023
Q1 | $1.16M | Buy |
17,662
+7,360
| +71% | +$425K | ﹤0.01% | 832 |
|
|
2022
Q4 | $533K | Sell |
10,302
-35,849
| -78% | -$1.9M | ﹤0.01% | 908 |
|
|
2022
Q3 | $3.15M | Buy |
46,151
+31,355
| +212% | +$1.86M | 0.01% | 602 |
|
|
2022
Q2 | $669K | Buy |
14,796
+10,749
| +266% | +$490K | ﹤0.01% | 909 |
|
|
2022
Q1 | $206K | Buy |
+4,047
| New | +$179K | ﹤0.01% | 1289 |
|
Other funds holding APLS
Mackenzie Financial's APLS Position: Q2 2026 in Review
Mackenzie Financial sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 153,330 shares — an estimated $6.17M sold.
Mackenzie Financial first reported a position in APLS in Q1 2022 and held it in 16 quarters. The position peaked at $6.17M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Mackenzie Financial reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Mackenzie Financial sold 153,330 Apellis Pharmaceuticals shares in Q2 2026, an estimated $6.17M.
- Mackenzie Financial first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 16 quarters.
- Mackenzie Financial's Apellis Pharmaceuticals position peaked at $6.17M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Mackenzie Financial's 13F filing for Q2 2026, filed 13 Aug 2026.